Filing Analysis
Harvard Apparatus Regenerative Technology, Inc. reported the results of its Annual Meeting of Stockholders held on June 18, 2026. The meeting included the election of three Class I Directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 18, 2026.
- Junli (Jerry) He, James Shmerling, and Mao Zhang were elected as Class I Directors for one-year terms.
- Stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- A non-binding advisory vote (Say-on-Pay) approved the compensation of named executive officers with 12,467,264 votes in favor.
Harvard Apparatus Regenerative Technology, Inc. entered into an exclusive global distribution agreement with Health Regen, Inc. for its consumer health and dietary supplement products. The agreement is set to run from November 1, 2024, through December 31, 2030.
🚩 Red Flags
- High termination penalty: The requirement to pay 3x projected Year 6 sales if the company terminates the deal creates significant contingent liability and limits strategic flexibility.
- Exclusivity risk: Global exclusivity prevents the company from seeking other distribution partners for these products until 2031.
📋 Key Facts
- Agreement signed on October 31, 2024, with Health Regen, Inc. (the 'Distributor').
- Exclusivity period: November 1, 2024, to December 31, 2030.
- The Company is granted global exclusivity; it cannot authorize other third parties to sell the Products during this term.
- Revenue model includes a mark-up fee on manufacturing costs and pass-through for procured services.
- Termination penalty: If the Company terminates early, it must pay the Distributor three times the projected annual sales in year 6 of the agreement.
Harvard Apparatus Regenerative Technology, Inc. announced the appointment of Mao Zhang to its Board of Directors as a Class I director, effective August 26, 2024.
📋 Key Facts
- Mao Zhang (Founder and CEO of Stellars Capital) appointed as Class I Director on August 26, 2024.
- Term runs until the 2026 annual meeting or until successor is elected/qualified.
- Compensation includes $25,000 in stock options vesting over one year (quarterly increments).
- Annual cash compensation of $20,000 paid in quarterly increments.
- Standard reimbursement for board and committee meeting expenses.
Harvard Apparatus Regenerative Technology, Inc. entered into a $5.0 million private placement agreement with an investor for the purchase of 1,388,888 shares at $3.60 per share. The deal includes significant governance concessions, including a Board seat for the investor and proposed charter amendments to allow special meetings and eliminate director classification.
🚩 Red Flags
- Significant governance concessions: The investor is gaining a Board seat and influence over corporate structure.
- Potential for activist-style control: Provisions allowing special meetings and declassifying the board are typical outcomes of distressed financing or aggressive investor intervention.
- Dilutive event: Issuance of 1.38M shares in a private placement.
📋 Key Facts
- Private placement of 1,388,888 shares of common stock.
- Aggregate purchase price: approximately $5.0 million.
- Purchase price per share: $3.60.
- Investor to appoint one member to the Board of Directors.
- Company to seek stockholder approval to eliminate director classification (declassifying the board).
- Company to seek stockholder approval to allow special meetings called by holders of at least 35% of voting power.
Harvard Apparatus Regenerative Technology, Inc. reported the results of its Annual Meeting of Stockholders held on June 20, 2024. The meeting included the election of three Class II Directors and the ratification of Marcum LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- David Green, Ting Li, and Ronald Packard were elected to the Board of Directors for three-year terms ending in 2027.
- Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- A non-binding advisory vote (Say-on-Pay) approved the compensation of named executive officers with 8,033,183 votes in favor.
Harvard Apparatus Regenerative Technology, Inc. entered into a private placement agreement to raise $1.5 million through the sale of 367,767 shares of common stock at a price of $4.03 per unit.
🚩 Red Flags
- Dilutive event: Issuance of new equity shares to private investors.
📋 Key Facts
- Date of Agreement: April 15, 2024
- Total aggregate purchase price: $1.5 million
- Number of shares to be issued: 367,767 shares of common stock
- Price per unit: $4.03
- Transaction type: Private placement under Section 4(a)(2) and Rule 506 exemptions
The Company entered into a $500,000 Bridge Note agreement with its Chairman and CEO, Junli He, on February 1, 2024. The loan carries an 8% annual interest rate and is repayable upon the next capital raise of at least $5 million or by February 1, 2025.
🚩 Red Flags
- Related-party transaction involving the CEO/Chairman
- Bridge financing indicates immediate liquidity needs
- The loan includes an optional conversion feature at the discretion of the insider, which can lead to significant dilution for existing shareholders
- Repayment is tied to a specific capital raise threshold ($5M), suggesting potential cash flow constraints
📋 Key Facts
- Lender: Junli He (Chairman and CEO)
- Principal Amount: $500,000
- Interest Rate: 8% annual fixed rate
- Maturity Date: February 1, 2025, or upon a capital raise of at least $5,000,000 (whichever is earlier)
- Conversion Feature: Optional conversion at the discretion of the Lender (CEO)